Business Context and Reporting Period
This Form 8-K, filed on January 5, 2015, reports on events occurring as of December 31, 2014, regarding Becton, Dickinson and Company (BD) and its proposed acquisition of CareFusion Corporation. The filing serves as a supplement to the definitive proxy statement/prospectus, detailing the settlement of stockholder class action lawsuits challenging the merger and providing additional disclosures regarding the negotiation process, financial advisor opinions, and prospective financial information.
Key Financial Metrics and Valuation
The filing does not report historical revenue, profit, or cash flow for BD or CareFusion for the period ended December 31, 2014. Instead, it presents valuation metrics and forward-looking projections used to justify the merger consideration of $58.00 per CareFusion share.
- Merger Consideration: $58.00 per share of CareFusion common stock (mix of cash and BD stock).
- Financial Advisor Opinion (Perella Weinberg): Rendered an opinion that the consideration was fair from a financial point of view.
- Comparable Company Analysis (CareFusion):
- Implied value range based on 2015E EBITDA multiples: $42.50 to $51.75 per share.
- Implied value range based on 2015E EPS multiples: $40.75 to $49.00 per share.
- Discounted Cash Flow (CareFusion):
- Management Case 1 Implied Value: $46.00 to $58.00 per share.
- Management Case 2 Implied Value: $50.00 to $63.25 per share.
- Comparable Company Analysis (BD):
- Implied value range based on 2015E EBITDA: $101.50 to $137.50 per share.
- Implied value range based on 2015E EPS: $103.25 to $130.75 per share.
- BD Closing Market Price (Oct 3, 2014): $115.84 per share.
Material Changes and Negotiation History
The filing discloses specific details regarding the negotiation timeline and board decisions that were not fully detailed in the initial proxy statement:
- Settlement of Litigation: On December 31, 2014, parties in the Delaware class action lawsuits entered a memorandum of understanding to settle the actions. Defendants agreed to supplemental disclosures to avoid litigation costs without admitting wrongdoing. The settlement does not affect the merger consideration or the timing of the special stockholder meeting scheduled for January 21, 2015.
- Unsolicited Proposal (2013): In January 2013, CareFusion received an unsolicited acquisition proposal which the board rejected as inadequate after retaining Morgan Stanley as a financial advisor.
- Financial Advisor Retention: CareFusion retained Perella Weinberg Partners LP on April 23, 2014, to advise on potential acquisitions and a potential sale of the company.
- Negotiation Dynamics:
- On September 8, 2014, BD was unwilling to raise its offer to $60.00 per share. BD presented a revised indication of interest at $57.00 per share, which CareFusion rejected.
- Both parties agreed to proceed with negotiations at an indicative price of $58.00 per share, a price previously supported by both boards.
- On September 25, 2014, BD indicated a desire to increase the cash portion of the consideration to over 70% of the total value.
- On September 25, 2014, BD confirmed that CareFusion CEO Mr. Gallahue would not join the combined company, a topic not previously discussed.
Prospective Financial Information (CareFusion)
The filing includes unaudited prospective financial information for CareFusion under two management cases (2015E-2024E). Key projections for 2015E include:
| Metric | Management Case 1 (2015E) | Management Case 2 (2015E) |
|---|---|---|
| Revenues | $4,080 million | $4,100 million |
| Adjusted EBITDA | $989 million | $999 million |
| EBITDA | $931 million | $937 million |
| Unlevered Free Cash Flow | $552 million | $555 million |
Guidance, Risks, and Contingencies
Outlook and Risks: The filing contains extensive forward-looking statements regarding the anticipated benefits of the combination, including estimated synergies. Management notes that actual results may differ materially due to risks including:
- Failure to obtain regulatory approvals or delays in closing.
- Integration challenges and failure to realize anticipated synergies.
- Outcome of legal proceedings related to the merger.
- Access to financing for debt refinancing.
- Changes in healthcare funding, reimbursement rates, and pricing pressures.
- Product liability claims and regulatory approval delays for new products.
Contingencies: The settlement of the Delaware actions is contingent upon final approval by the Delaware Court of Chancery. If approved, it will release all claims challenging the merger (excluding appraisal rights).
Investor Verification Checklist
- Verify the final approval status of the Delaware Court of Chancery regarding the settlement of the stockholder class action lawsuits.
- Confirm the outcome of the CareFusion special stockholder meeting scheduled for January 21, 2015, to adopt the merger agreement.
- Review the definitive proxy statement/prospectus for the full text of the merger agreement and the complete financial advisor opinions.
- Monitor regulatory approval status from relevant government bodies required to close the transaction.
- Assess the accuracy of the prospective financial information (Management Case 1 and 2) against actual performance post-merger.